Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | NAT1 | P18440 | 2/20 | 0.75 |
| ▸ | MRE11 | P49959 | 1/20 | 0.75 |
| ▸ | PNP | P00491 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 5/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.70 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | NSD2 | O96028 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621990 | 1.00 | TDP1 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| SCHEMBL621991 | 1.00 | TDP1 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| SCHEMBL8534665 | 0.86 | NAT1 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| Mirin SCHEMBL15421606 | 0.86 | MRE11 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| Mirin SCHEMBL21296287 | 0.86 | MRE11 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| SCHEMBL8174883 | 0.86 | NAT1 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| SCHEMBL8174880 | 0.86 | NAT1 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| Mirin SCHEMBL15421605 | 0.86 | MRE11 (1.00) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| SCHEMBL1249051 | 0.85 | GSK3B (0.73) | TDP1HPGDAKR1B1GSK3BRAB9A | |
| SCHEMBL1249053 | 0.85 | GSK3B (0.73) | TDP1HPGDAKR1B1GSK3BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216148-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-12-22 | — | — | US | claimed |
| US-20140023603-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2014-01-23 | — | — | US | claimed |
| US-9896421-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2018-02-20 | — | — | US | disclosed |
| EP-2603498-B1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | OCTETA THERAPEUTICS LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2603507-B1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEV CO LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | disclosed |
| US-9216148-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-12-22 | — | — | US | disclosed |
| US-8946435-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8933240-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933240-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140378687-A1 | Synthesis for Thiazolidinedione Compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC | 2014-12-25 | — | — | US | disclosed |
| US-20130204008-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130204008-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013105753-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2013-07-18 | — | — | WO | disclosed |
| EP-2603507-A1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | Metabolic Solutions Development Company LLC (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021467-A1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021476-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023603-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PPARG, PPARA, PPARD | TDP1 1138/4885HPGD 489/4885AKR1B1 958/4885 |
| US-20130204008-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | PPARG, PPARD, PPARA | TDP1 4280/4885HPGD 264/4885AKR1B1 328/4885 |
| US-20140378687-A1 | Synthesis for Thiazolidinedione Compounds | PPARD, PPARG, PPARA | TDP1 4263/4885HPGD 233/4885AKR1B1 291/4885 |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | TDP1 1176/4885HPGD 681/4885AKR1B1 1583/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | TDP1 4829/4885HPGD 3478/4885AKR1B1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.